Long-Term Virological Outcome in Patients Infected with Multi-Nucleoside Analogue-Resistant HIV-1

The emergence of HIV strains that are resistant to anti-retroviral drugs is a major cause of treatment failure. Two sets of mutations: the Q151M complex and the 69 insert, cause resistance to multiple nucleoside analogues. We report the response to treatment in 12 patients with multiple NRTI-resistant HIV-1 strains. Seven of 12 patients (58%) were able to maintain a viral load below 200 copies/ml at week 48. The patients most likely to obtain therapeutic success were those having no or low-level resistance to non-nucleoside reverse transcriptase inhibitors and/or protease inhibitors. New and more effective drugs are needed for patients with HIV-1 that is resistant to more than one of the current three classes of HIV drugs.

[1]  N. Graham,et al.  Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens. , 2001, AIDS research and human retroviruses.

[2]  K. Hertogs,et al.  ANTIVIRAL ACTIVITY OF TENOFOVIR (PMPA) AGAINST NUCLEOSIDE-RESISTANT CLINICAL HIV SAMPLES , 2001, Nucleosides, nucleotides & nucleic acids.

[3]  A. Hatzakis,et al.  Virological and Immunological Response to HAART Therapy in a Community-Based Cohort of HIV-1-Positive Individuals , 2001, HIV clinical trials.

[4]  M. Moroni,et al.  Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure. , 2000, Journal of acquired immune deficiency syndromes.

[5]  B. Larder,et al.  Mutational Patterns in the HIV Genome and Cross-Resistance following Nucleoside and Nucleotide Analogue Drug Exposure , 2000, Antiviral therapy.

[6]  Á. Holguín,et al.  Multiple Drug Resistance Genotype Causing Failure of Antiretroviral Treatment in an HIV-Infected Patient Heavily Exposed to Nucleoside Analogues , 1999, European Journal of Clinical Microbiology and Infectious Diseases.

[7]  W. Sugiura,et al.  Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors. , 1999, Journal of human virology.

[8]  M. Hillebrand,et al.  Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. , 1999, AIDS.

[9]  D. Katzenstein,et al.  A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. , 1998, The Journal of clinical investigation.

[10]  H. Mitsuya,et al.  Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. , 1998, The Journal of infectious diseases.

[11]  V. Soriano,et al.  Different Outcome in the First Two Patients with an HIV-1 Multinucleoside Drug-Resistant T69SSS Insertion in Spain , 1998, Antiviral therapy.

[12]  E. Arnold,et al.  Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[13]  C. Torti,et al.  HIV-1 multi-dideoxynucleoside resistance mutation (Q151M): prevalence, associated resistance mutations and response to antiretroviral salvage treatment. , 2001, Microbios.

[14]  M. Peeters,et al.  Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. , 2001 .

[15]  D. Richman.  Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance. , 1996, Advances in experimental medicine and biology.